Search

Your search keyword '"Asnaghi, Veronica"' showing total 22 results
Start Over Author "Asnaghi, Veronica"
22 results on '"Asnaghi, Veronica"'

1. Efficacy and safety of emapalumab in macrophage activation syndrome

Author

De Benedetti, Fabrizio, primary, Grom, Alexei A, additional, Brogan, Paul A, additional, Bracaglia, Claudia, additional, Pardeo, Manuela, additional, Marucci, Giulia, additional, Eleftheriou, Despina, additional, Papadopoulou, Charalampia, additional, Schulert, Grant S, additional, Quartier, Pierre, additional, Antón, Jordi, additional, Laveille, Christian, additional, Frederiksen, Rikke, additional, Asnaghi, Veronica, additional, Ballabio, Maria, additional, Jacqmin, Philippe, additional, and de Min, Cristina, additional

Published
2023
Full Text
View/download PDF

2. Efficacy and safety of emapalumab in macrophage activation syndrome

Author

De Benedetti, Fabrizio, primary, Grom, Alexei A, additional, Brogan, Paul, additional, Bracaglia, Claudia, additional, Pardeo, Manuela, additional, Marucci, Giulia, additional, Eleftheriou, Despina, additional, Papadopoulou, Charalampia, additional, Schulert, Grant S, additional, Quartier, Pierre, additional, Antón, Jordi, additional, Laveille, Christian, additional, Frederiksen, Rikke, additional, Asnaghi, Veronica, additional, Ballabio, Maria, additional, Jacqmin, Philippe, additional, and de Min, Cristina, additional

Published
2022
Full Text
View/download PDF

3. Emapalumab treatment in an ADA-SCID patient with refractory hemophagocytic lymphohistiocytosis-related graft failure and disseminated BCGitis

Author

Tucci, Francesca, Gallo, Vera, Barzaghi, Federica, Ferrua, Francesca, Migliavacca, Maddalena, Calbi, Valeria, Doglio, Matteo, Fratini, Elena Sophia, Karakas, Zeynep, Guner, Sukru, Zambelli, Matilde, Parisi, Cristina, Milani, Raffaella, Gattillo, Salvatore, Mazzi, Benedetta, Oltolini, Chiara, Barbera, Maurizio, Baldoli, Cristina, Cirillo, Daniela Maria, Asnaghi, Veronica, De Min, Cristina, Cicalese, Maria Pia, Ciceri, Fabio, Aiuti, Alessandro, Bernardo, Maria Ester, Tucci, Francesca, Gallo, Vera, Barzaghi, Federica, Ferrua, Francesca, Migliavacca, Maddalena, Calbi, Valeria, Doglio, Matteo, Fratini, Elena Sophia, Karakas, Zeynep, Guner, Sukru, Zambelli, Matilde, Parisi, Cristina, Milani, Raffaella, Gattillo, Salvatore, Mazzi, Benedetta, Oltolini, Chiara, Barbera, Maurizio, Baldoli, Cristina, Cirillo, Daniela Maria, Asnaghi, Veronica, De Min, Cristina, Cicalese, Maria Pia, Ciceri, Fabio, Aiuti, Alessandro, and Bernardo, Maria Ester

Subjects
hemophagocytic lymphohistiocytosis, monoclonal antibody, graft failure, Immunodeficiencies, Stem Cell Transplantation
Abstract

Emapalumab, a fully human anti-IFNγ monoclonal antibody, has been approved in the US as second-line treatment of primary hemophagocytic lymphohistiocytosis (HLH) patients and has shown promise in patients with graft failure (GF) requiring a second allogeneic hematopoietic stem cell transplantation (HSCT). The blockade of IFNγ activity may increase the risk of severe infections, including fatal mycobacteriosis. We report a case of secondary HLH-related GF in the context of HLA-haploidentical HSCT successfully treated with emapalumab in the presence of concomitant life-threatening infections, including disseminated tuberculosis (TB). A 4 years old girl with Adenosine Deaminase-Severe Combined Immunodeficiency complicated by disseminated TB came to our attention for ex-vivo hematopoietic stem cell-gene therapy. After engraftment failure of gene corrected cells, she received two HLA-haploidentical T-cell depleted HSCT from the father, both failed due to GF related to concomitant multiple infections and secondary HLH. Emapalumab administration allowed to control HLH, as well as to prevent GF after a third haplo-HSCT from the mother. Remarkably, all infections improved with antimicrobial medications and disseminated TB did not show any reactivation. This seminal case supports emapalumab use for treatment of secondary HLH and prevention of GF in patients undergoing haplo-HSCT even in the presence of multiple infections, including TB.

Published
2020

4. Macrophage Activation Syndrome (MAS) in Systemic Juvenile Idiopathic Arthritis (sJIA): Treatment with Emapalumab, an Anti-Interferon Gamma (IFNγ) Monoclonal Antibody

Author

De Benedetti, Fabrizio, primary, Grom, Alexei A, additional, Brogan, Paul, additional, Bracaglia, Claudia, additional, Pardeo, Manuela, additional, Marucci, Giulia, additional, Eleftheriou, Despina, additional, Papadopoulou, Charalampia, additional, Quartier, Pierre, additional, Antón, Jordi, additional, Frederiksen, Rikke, additional, Asnaghi, Veronica, additional, Ballabio, Maria, additional, and de Min, Cristina, additional

Published
2021
Full Text
View/download PDF

14. P2‐003: Clinical Trial Design of Cread: A Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group Phase 3 Study to Evaluate Crenezumab Treatment in Patients with Prodromal‐To‐Mild Alzheimer’s Disease

Author

Blaettler, Thomas, primary, Smith, Janice, additional, Smith, Jillian, additional, Paul, Robert, additional, Asnaghi, Veronica, additional, Fuji, Reina, additional, Quartino, Angelica, additional, Honigberg, Lee, additional, Rabbia, Michael A., additional, Yule, Susan, additional, Ostrowitzki, Susanne, additional, and Fontoura, Paulo, additional

Published
2016
Full Text
View/download PDF

17. Low Ca2+ pump activity in diabetic nephropathy

Author

Podestá, Francesca, primary, Meregalli, Giancarla, additional, Ghelardi, Renata, additional, Del Giudice, Rosmina, additional, Asnaghi, Veronica, additional, Maestroni, Anna, additional, and Zerbini, Gianpaolo, additional

Published
2001
Full Text
View/download PDF

18. Activation of nuclear factor-kappaB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes.

Author

Romeo, Giulio, Liu, Wei-Hua, Asnaghi, Veronica, Kern, Timothy S, and Lorenzi, Mara

Abstract

To reconstruct the events that may contribute to the accelerated death of retinal vascular cells in diabetes, we investigated in situ and in vitro the activation of nuclear factor-kappaB (NF-kappaB), which is triggered by cellular stress and controls several programs of gene expression. The retinal capillaries of diabetic eye donors showed an increased number of pericyte nuclei positive for NF-kappaB, when compared with nondiabetic donors, whereas endothelial cells were negative. Microvascular cell apoptosis and acellular capillaries were increased only in the diabetic donors with numerous NF-kappaB-positive pericytes. Likewise, high glucose in vitro activated NF-kappaB in retinal pericytes but not in endothelial cells, and increased apoptosis only in pericytes. Studies with NF-kappaB inhibitors suggested that in pericytes, basal NF-kappaB has prosurvival functions, whereas NF-kappaB activation induced by high glucose is proapoptotic. Pericytes exposed to high glucose showed increased expression of Bax and of tumor necrosis factor-alpha, which were prevented by the NF-kappaB inhibitors and mimicked by transfection with the p65 subunit of NF-kappaB, and failed to increase the levels of the NF-kappaB-dependent inhibitors of apoptosis. Colocalization of activated NF-kappaB and Bax overexpression was observed in the retinal pericytes of diabetic donors. A proapoptotic program triggered by NF-kappaB selectively in retinal pericytes in response to hyperglycemia is a possible mechanism for the early demise of pericytes in diabetic retinopathy. [ABSTRACT FROM AUTHOR]

Published
2002
Full Text
View/download PDF

19. Low Ca2+pump activity in diabetic nephropathy

Author

Podestá, Francesca, Meregalli, Giancarla, Ghelardi, Renata, Del Giudice, Rosmina, Asnaghi, Veronica, Maestroni, Anna, and Zerbini, Gianpaolo

Abstract

Elevated cell Na+-H+exchange (NHE) activity characterizes diabetic nephropathy (DN), but the mechanisms of this abnormality are unclear. Recent evidence suggests that NHE and the Ca2+pump share similar regulatory pathways, but whether abnormalities in Ca2+metabolism characterize DN is not known. We investigated Ca2+efflux rates, NHE activity, cytosolic Ca2+([Ca2+]i) concentrations, and intracellular pH (pHi) in human skin fibroblasts from 20 patients with type 1 (insulin-dependent) diabetes and nephropathy; 20 patients with diabetes with normoalbuminuria matched for age, sex, and duration of diabetes; and 10 individuals without diabetes. Ca2+pump-mediated Ca2+efflux was significantly lower in patients with nephropathy than in patients with normoalbuminuria and individuals without diabetes (0.074 ± 0.01 versus 0.115 ± 0.01 versus 0.131 ± 0.02 nmol·mgprotein−1·min−1; analysis of variance [ANOVA], P= 0.015). Elevated maximal velocity of the Na+-H+exchanger was confirmed in fibroblasts from patients with nephropathy (14.4 ± 1.2 versus 7.1 ± 0.7 versus 8.0 ± 1.2 mmol H+·l cell−1·min−1; ANOVA, P< 0.0001). A reverse correlation between Ca2+pump activity and NHE rates could be shown. Adjustment for glycated hemoglobin and plasma lipid levels did not affect these findings. Finally, [Ca2+]iconcentrations and pHiwere normal in all patients. Low Ca2+pump activity is a concomitant event of elevated NHE rates in DN; the molecular dysfunction(s) underlying these abnormalities remains to be established. © 2001 by the National Kidney Foundation, Inc.

Published
2001
Full Text
View/download PDF

22. Emapalumab treatment in an ADA-SCID patient with refractory hemophagocytic lymphohistiocytosis-related graft failure and disseminated bacillus Calmette-Guérin infection.

Author

Tucci F, Gallo V, Barzaghi F, Ferrua F, Migliavacca M, Calbi V, Doglio M, Fratini ES, Karakas Z, Guner S, Zambelli M, Parisi C, Milani R, Gattillo S, Mazzi B, Oltolini C, Barbera M, Baldoli C, Cirillo DM, Asnaghi V, De Min C, Cicalese MP, Ciceri F, Aiuti A, and Bernardo ME

Subjects
Adenosine Deaminase, Agammaglobulinemia, Antibodies, Monoclonal therapeutic use, Antibodies, Neutralizing, BCG Vaccine, Child, Preschool, Female, Humans, Hematopoietic Stem Cell Transplantation adverse effects, Lymphohistiocytosis, Hemophagocytic drug therapy, Lymphohistiocytosis, Hemophagocytic etiology, Severe Combined Immunodeficiency complications, Severe Combined Immunodeficiency drug therapy, Tuberculosis complications, Tuberculosis drug therapy
Abstract

Emapalumab, a fully human anti-IFNγ monoclonal antibody, has been approved in the US as second-line treatment of primary hemophagocytic lymphohistiocytosis (HLH) patients and has shown promise in patients with graft failure (GF) requiring a second allogeneic hematopoietic stem cell transplantation (HSCT). The blockade of IFNγ activity may increase the risk of severe infections, including fatal mycobacteriosis. We report a case of secondary HLH-related GF in the context of HLA-haploidentical HSCT successfully treated with emapalumab in the presence of concomitant life-threatening infections, including disseminated tuberculosis (TB). A 4 years old girl with Adenosine Deaminase-Severe Combined Immunodeficiency complicated by disseminated TB came to our attention for ex-vivo hematopoietic stem cell-gene therapy. After engraftment failure of gene corrected cells, she received two HLA-haploidentical T-cell depleted HSCT from the father, both failed due to GF related to concomitant multiple infections and secondary HLH. Emapalumab administration allowed to control HLH, as well as to prevent GF after a third haplo-HSCT from the mother. Remarkably, all infections improved with antimicrobial medications and disseminated TB did not show any reactivation. This seminal case supports emapalumab use for treatment of secondary HLH and prevention of GF in patients undergoing haplo-HSCT even in the presence of multiple infections, including TB.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results